<DOC>
	<DOCNO>NCT03064243</DOCNO>
	<brief_summary>Apatinib kind innovative medicine approve China Food Drug Administration（CFDA） , research Jiangsu Hengrui Pharmaceutical Co. , Ltd. Apatinib kinase inhibitor receptor tyrosine VEGFR2 . The protocol explore Apatinib effectiveness advance soft tissue sarcoma safety .</brief_summary>
	<brief_title>A Phase II Study Apatinib STS Patients</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Signed informed consent . Histologically proven advance soft tissue sarcoma , At least one measurable lesion . Including : Synovial sarcoma , leiomyosarcoma , Alveolar soft part sarcoma , Undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma , Liposarcoma , Fibrosarcoma , Clear cell sarcoma , Epithelioid sarcoma , Angiosarcoma , Spindle cell sarcoma , rhabdomyosarcoma treat chemotherapy , Ewing 's sarcoma soft tissue/Primitive neuroectodermal tumor . Excluding : Malignant peripheral nerve sheath tumor , chondrosarcoma , Dermatofibrosarcoma protuberans , Gastrointestinal stromal tumor , Inflammatory myofibroblastic sarcoma , Malignant mesothelioma . Must evidence unresectable residual disease . In last 6 month , least one chemotherapy regimen ( include anthracyclines ) use patient fail unable tolerate treatment . ECOG ps≤2 . Life expectancy : 3 month . Prior aptinib less 2 week least 1 month since prior aptinib；at least 1 month since prior inhibitor mTOR EGFR pathway . Not pregnant nursing；Fertile patient must use effective contraception . Hematopoietic HB≥90g/L Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 80,000/mm^3 Uncontrollable hypertension ; Has influence oral drug ; Patients high risk gastrointestinal blooding ; INR &gt; 1.5×ULN，APTT &gt; 1.5×ULN ; Allergic ingredient product ; Less 1 month since last major surgery ; Brain metastasis ; With second cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>